1. Targeted repair of heart injury by stem cells fused with platelet nanovesicles
- Author
-
Jhon Cores, Zegen Wang, Leonard J. Lobo, Jinying Zhang, Michael Taylor Hensley, Laura Ruterbories, Phuong-Uyen Dinh, Erin P. Sproul, Ke Cheng, Tao-Sheng Li, Tyler A. Allen, Adam C. Vandergriff, Junnan Tang, Zhen Gu, Alex M. Lynch, Ke Huang, George A. Stouffer, Deliang Shen, Thomas G. Caranasos, Ashley C. Brown, Teng Su, and Emily Mihalko
- Subjects
0301 basic medicine ,Heart Injury ,Cell type ,business.industry ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,02 engineering and technology ,021001 nanoscience & nanotechnology ,Infarct size ,medicine.disease ,Article ,Parental cell ,Computer Science Applications ,Transplantation ,03 medical and health sciences ,030104 developmental biology ,Cancer research ,Medicine ,Platelet ,Myocardial infarction ,Stem cell ,0210 nano-technology ,business ,Biotechnology - Abstract
Stem cell transplantation, as used clinically, suffers from low retention and engraftment of the transplanted cells. Inspired by the ability of platelets to recruit stem cells to sites of injury on blood vessels, we hypothesized that platelets might enhance the vascular delivery of cardiac stem cells (CSCs) to sites of myocardial infarction injury. Here, we show that CSCs with platelet nanovesicles fused onto their surface membranes express platelet surface markers that are associated with platelet adhesion to injury sites. We also find that the modified CSCs selectively bind collagen-coated surfaces and endothelium-denuded rat aortas, and that in rat and porcine models of acute myocardial infarction the modified CSCs increase retention in the heart and reduce infarct size. Platelet-nanovesicle-fused CSCs thus possess the natural targeting and repairing ability of their parental cell types. This stem cell manipulation approach is fast, straightforward and safe, does not require genetic alteration of the cells, and should be generalizable to multiple cell types.
- Published
- 2018